Proceedings of the International Conference “Health and wellbeing in modern society” (ICHW 2020)

In situ Testing of Biologically Active Dietary Supplement Hepar Formula in Children with Chronic Viral Hepatitis

Authors
A.A. Vekovtsev, N.A. Pleshkova, A.N. Avstrievskikh, V.M. Poznyakovsky
Corresponding Author
A.A. Vekovtsev
Available Online 3 October 2020.
DOI
10.2991/ahsr.k.201001.001How to use a DOI?
Keywords
biologically active dietary supplement, chronic viral hepatitis, Hepar Formula
Abstract

A new type of biologically active dietary supplement – BADS Hepar Formula was developed. The composition of BADS was justified, which proved to have synergistic properties forming a balanced complex for the maintenance of liver metabolic processes, protection and restoration of its cells in conditions of pathological changes. A possible mechanism of participation of functional ingredients of the developed product in relation to metabolic processes in liver diseases is presented. The purpose of the study is to carry out in situ tests of Hepar Formula among children with chronic viral hepatitis. Clinical evidence of functional properties of the new type of biologically active dietary supplement is provided. The therapeutic efficacy of the developed product is studied by including BADS in the diet of 20 children aged 9 to 14 years with chronic viral hepatitis B and C in the integration phase of the infectious process. Clinical symptoms were investigated in the dynamics of dietary therapy. By the end of the treatment, good and satisfactory results were reported in 90% of the children of the main group and 80 % of the control group. The developed product contributes to the improvement of adaptation capabilities of the child’s body. Side effects in the application of BADS Hepar Formula are not noted, which is essential for pediatric practice. It is possible to combine the developed product with other drugs. The results of in situ tests showed that the inclusion of BADS into the baseline therapy contributes to reparative processes in liver cells, accelerates tissue regeneration after inflammatory diseases, improves the general condition, has hepatoprotective and anti-inflammatory effects. The new kind of hepatoprotector can be used in prevention and complex treatment of chronic liver diseases. The opinion of the Expert Council of the Russian Federation was received, the developed product is included into the Federal BADS Register.

Copyright
© 2020, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

Volume Title
Proceedings of the International Conference “Health and wellbeing in modern society” (ICHW 2020)
Series
Advances in Health Sciences Research
Publication Date
3 October 2020
ISBN
10.2991/ahsr.k.201001.001
ISSN
2468-5739
DOI
10.2991/ahsr.k.201001.001How to use a DOI?
Copyright
© 2020, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - CONF
AU  - A.A. Vekovtsev
AU  - N.A. Pleshkova
AU  - A.N. Avstrievskikh
AU  - V.M. Poznyakovsky
PY  - 2020
DA  - 2020/10/03
TI  - In situ Testing of Biologically Active Dietary Supplement Hepar Formula in Children with Chronic Viral Hepatitis
BT  - Proceedings of the International Conference “Health and wellbeing in modern society” (ICHW 2020)
PB  - Atlantis Press
SP  - 1
EP  - 5
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.201001.001
DO  - 10.2991/ahsr.k.201001.001
ID  - Vekovtsev2020
ER  -